Evidence map›Paper›PMID 40551107›Full record

ArticleCancer cell international2025

Palmitoylation regulators drive the progression of clear cell renal cell carcinoma through Inhibition of cuproptosis: insights into the role of ZDHHC18.

Wei Xu, Xiao-Chao Chen, Yang Wang, Jian-Chun Chen, Zhi-Jun Cao, Ru Huang, Chao Chen, Dao-Rong Hou, Min-Jun Jiang, Chen Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wei Xu *Department of Emergency, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, 215200, China.
Xiao-Chao Chen *Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
Yang Wang *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Jian-Chun Chen *Department of Urology, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, 215200, China.
Zhi-Jun CaoDepartment of Urology, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, 215200, China.
Ru HuangDepartment of Urology, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, 215200, China.
Chao ChenDepartment of Urology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, 315010, Zhejiang, China.
Dao-Rong HouKey Laboratory of Model Animal Research, Animal Core Facility of Nanjing Medical University, Nanjing Medical University, Nanjing, 211166, China. houdaorong@njmu.edu.cn.
Min-Jun JiangDepartment of Urology, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, 215200, China. xcywj513@126.com.
Chen XuDepartment of Urology, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, 215200, China. chenadoc@126.com.

Funding

the Clinical trial institution capacity improvement project of Suzhou SLT2023021the Youth Project of "Gusu healthy" GSWS2022110Zhejiang province under Grant 2022RC250
6 · The paper itself

Abstract

backgroundProtein palmitoylation is a reversible post-translational modification that increases protein hydrophobicity, which can affect protein localization, stability, and function. Although palmitoylation is frequently observed in various cancers, the specific mechanisms by which it influences clear cell renal cell carcinoma (ccRCC) are still not well understood.

methodsThis study used transcriptome expression profiles and clinical characteristics of clear cell renal cell carcinoma (ccRCC) obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Kaplan-Meier (KM) survival analysis was performed to evaluate patient survival. Consensus clustering was applied to identify tumor palmitoylation patterns. A total of 101 different machine learning methods were used to develop predictive models. Functional enrichment analyses were conducted using Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and Gene Set Variation Analysis (GSVA).

resultsOf the 34 prognosis-related palmitoylation-related genes (PRGs), 29 were used to cluster patients in the TCGA-KIRC cohort, leading to the identification of four palmitoylation clusters. We developed a risk model and a nomogram based on palmitoylation scores to enhance risk classification. Functional analysis indicated that high-risk patients exhibited disrupted fatty acid metabolism. Correlation analysis identified ZDHHC18 as a potential hub gene associated with impaired fatty acid metabolism and cuproptosis. Finally, we validated the role of ZDHHC18 in ccRCC proliferation through in vitro experiments.

conclusionOur research demonstrated that PRGs play a crucial role in the development of clear cell renal cell carcinoma (ccRCC). A nomogram based on palmitoylation scores may accurately predict the prognosis of ccRCC patients. Furthermore, the palmitoylation regulator ZDHHC18 affects cuproptosis in ccRCC, which in turn impacts patient survival.

Indexed as

CcRCCCuproptosisProtein s-palmitoylationZDHHC18

Identifiers

PMID40551107
PMCPMC12186379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.